CHAMBER HILL STRATEGIES

Lobbying for OS THERAPIES · biotechnology company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · New York · House · Senate · posted Apr 6, 2026

Lobbying activity 2

Pharmacy

cancer immunotherapy and antibody treatment; osteosarcoma

Health Issues

cancer immunotherapy and antibody treatment; osteosarcoma

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.